Literature DB >> 26048147

HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.

Jun Li1, Jessica Heinrichs2, Kelley Haarberg1, Kenrick Semple1, Anandharaman Veerapathran1, Chen Liu3, Claudio Anasetti4, Xue-Zhong Yu5.   

Abstract

Naturally derived regulatory T cells (Tregs) may prevent graft-versus-host disease (GVHD) while preserving graft-versus-leukemia (GVL) activity. However, clinical application of naturally derived regulatory T cells has been severely hampered by their scarce availability and nonselectivity. To overcome these limitations, we took alternative approaches to generate Ag-specific induced Tregs (iTregs) and tested their efficacy and selectivity in the prevention of GVHD in preclinical models of bone marrow transplantation. We selected HY as a target Ag because it is a naturally processed, ubiquitously expressed minor histocompatibility Ag (miHAg) with a proven role in GVHD and GVL effect. We generated HY-specific iTregs (HY-iTregs) from resting CD4 T cells derived from TCR transgenic mice, in which CD4 cells specifically recognize HY peptide. We found that HY-iTregs were highly effective in preventing GVHD in male (HY(+)) but not female (HY(-)) recipients using MHC II-mismatched, parent→F1, and miHAg-mismatched murine bone marrow transplantation models. Interestingly, the expression of target Ag (HY) on the hematopoietic or nonhematopoietic compartment alone was sufficient for iTregs to prevent GVHD. Furthermore, treatment with HY-iTregs still preserved the GVL effect even against pre-established leukemia. We found that HY-iTregs were more stable in male than in female recipients. Furthermore, HY-iTregs expanded extensively in male but not female recipients, which in turn significantly reduced donor effector T cell expansion, activation, and migration into GVHD target organs, resulting in effective prevention of GVHD. This study demonstrates that iTregs specific for HY miHAgs are highly effective in controlling GVHD in an Ag-dependent manner while sparing the GVL effect.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26048147      PMCID: PMC4491008          DOI: 10.4049/jimmunol.1401250

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.

Authors:  Shoji Asakura; Daigo Hashimoto; Shuichiro Takashima; Haruko Sugiyama; Yoshinobu Maeda; Koichi Akashi; Mitsune Tanimoto; Takanori Teshima
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease.

Authors:  K L Hippen; S C Merkel; D K Schirm; C Nelson; N C Tennis; J L Riley; C H June; J S Miller; J E Wagner; B R Blazar
Journal:  Am J Transplant       Date:  2011-05-12       Impact factor: 8.086

3.  TGF-beta-induced myelin peptide-specific regulatory T cells mediate antigen-specific suppression of induction of experimental autoimmune encephalomyelitis.

Authors:  Hong Zhang; Joseph R Podojil; Judy Chang; Xunrong Luo; Stephen D Miller
Journal:  J Immunol       Date:  2010-05-07       Impact factor: 5.422

4.  A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease.

Authors:  Isao Tawara; Warren D Shlomchik; Angela Jones; Weiping Zou; Evelyn Nieves; Chen Liu; Tomomi Toubai; Raimon Duran-Struuck; Yaping Sun; Shawn G Clouthier; Rebecca Evers; Kathleen P Lowler; Robert B Levy; Pavan Reddy
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

5.  Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice.

Authors:  Kenrick Semple; Yu Yu; Dapeng Wang; Claudio Anasetti; Xue-Zhong Yu
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-09       Impact factor: 5.742

6.  Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease.

Authors:  Amy Beres; Richard Komorowski; Masahiko Mihara; William R Drobyski
Journal:  Clin Cancer Res       Date:  2011-05-10       Impact factor: 12.531

7.  Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.

Authors:  Keli L Hippen; Sarah C Merkel; Dawn K Schirm; Christine M Sieben; Darin Sumstad; Diane M Kadidlo; David H McKenna; Jonathan S Bromberg; Bruce L Levine; James L Riley; Carl H June; Phillip Scheinberg; Daniel C Douek; Jeffrey S Miller; John E Wagner; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2011-05-18       Impact factor: 17.956

8.  Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning.

Authors:  N Pilat; U Baranyi; C Klaus; E Jaeckel; N Mpofu; F Wrba; D Golshayan; F Muehlbacher; T Wekerle
Journal:  Am J Transplant       Date:  2010-02-10       Impact factor: 8.086

9.  Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD.

Authors:  Christian Koenecke; Niklas Czeloth; Anja Bubke; Susanne Schmitz; Adrien Kissenpfennig; Bernard Malissen; Jochen Huehn; Arnold Ganser; Reinhold Förster; Immo Prinz
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

10.  All-trans retinoic acid promotes TGF-β-induced Tregs via histone modification but not DNA demethylation on Foxp3 gene locus.

Authors:  Ling Lu; Jilin Ma; Zhiyuan Li; Qin Lan; Maogen Chen; Ya Liu; Zanxian Xia; Julie Wang; Yuanping Han; Wei Shi; Valerie Quesniaux; Bernhard Ryffel; David Brand; Bin Li; Zhongmin Liu; Song Guo Zheng
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

View more
  12 in total

1.  Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation.

Authors:  Yue Hu; Gan-Lin He; Xiang-Yu Zhao; Xiao-Su Zhao; Yu Wang; Lan-Ping Xu; Xiao-Hui Zhang; Xue-Zhong Yu; Kai-Yan Liu; Ying-Jun Chang; Xiao-Jun Huang
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

2.  CD8(+) Tregs promote GVHD prevention and overcome the impaired GVL effect mediated by CD4(+) Tregs in mice.

Authors:  Jessica Heinrichs; Jun Li; Hung Nguyen; Yongxia Wu; David Bastian; Anusara Daethanasanmak; M-Hanief Sofi; Steven Schutt; Chen Liu; Junfei Jin; Brian Betts; Claudio Anasetti; Xue-Zhong Yu
Journal:  Oncoimmunology       Date:  2016-03-28       Impact factor: 8.110

3.  Regulatory T-Cell Therapy for Graft-versus-host Disease.

Authors:  Jessica Heinrichs; David Bastian; Anandharaman Veerapathran; Claudio Anasetti; Brain Betts; Xue-Zhong Yu
Journal:  J Immunol Res Ther       Date:  2016-04-28

Review 4.  Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD.

Authors:  Bruce R Blazar; Geoffrey R Hill; William J Murphy
Journal:  Nat Rev Clin Oncol       Date:  2020-04-20       Impact factor: 66.675

5.  First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings.

Authors:  Margaret L MacMillan; Keli L Hippen; David H McKenna; Diane Kadidlo; Darin Sumstad; Todd E DeFor; Claudio G Brunstein; Shernan G Holtan; Jeffrey S Miller; Erica D Warlick; Daniel J Weisdorf; John E Wagner; Bruce R Blazar
Journal:  Blood Adv       Date:  2021-03-09

6.  Early myeloid-derived suppressor cells (HLA-DR-/lowCD33+CD16-) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT.

Authors:  Ke Wang; Meng Lv; Ying-Jun Chang; Xiang-Yu Zhao; Xiao-Su Zhao; Yuan-Yuan Zhang; Yu-Qian Sun; Zhi-Dong Wang; Pan Suo; Yang Zhou; Dan Liu; Shu-Zhen Zhai; Yan Hong; Yu Wang; Xiao-Hui Zhang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2019-03-18       Impact factor: 17.388

Review 7.  Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease.

Authors:  Govindarajan Thangavelu; Bruce R Blazar
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

Review 8.  Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.

Authors:  Ying-Jun Chang; Xiang-Yu Zhao; Xiao-Jun Huang
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

Review 9.  Foxp3 Instability Helps tTregs Distinguish Self and Non-self.

Authors:  Zhongmei Zhang; Xuyu Zhou
Journal:  Front Immunol       Date:  2019-09-24       Impact factor: 7.561

10.  A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants.

Authors:  James M Mathew; Jessica H-Voss; Ann LeFever; Iwona Konieczna; Cheryl Stratton; Jie He; Xuemei Huang; Lorenzo Gallon; Anton Skaro; Mohammed Javeed Ansari; Joseph R Leventhal
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.